thiazoles has been researched along with Cardiometabolic Syndrome in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (62.75) | 29.6817 |
| 2010's | 18 (35.29) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Coid, J; Deng, W; Guo, W; Hu, X; Li, K; Li, L; Li, T; Li, X; Li, Y; Lu, T; Lv, L; Ma, X; Ren, H; Reynolds, GP; Tan, L; Tan, Q; Tian, Y; Wang, C; Wang, H; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Cox, RL | 1 |
| An, Y; Beason-Held, LL; Bilgel, M; Ferrucci, L; Gomez, G; Resnick, SM; Studenski, S; Wong, DF | 1 |
| Cammisotto, PG; Campeau, L; Mossa, A; Nguyen, H; Velasquez Flores, M | 1 |
| Farrell, GC; Gillard, J; Horsmans, Y; Leclercq, IA; Poekes, L | 1 |
| Chen, AP; Juang, YY; Lee, CP | 1 |
| Li, CH; Rao, SZ; Shi, L; Zhan, GL; Zhang, H | 1 |
| Boyd, S; deSchoolmeester, J; Dossetter, AG; Goldberg, FW; Groombridge, SD; Gutierrez, PM; Kemmitt, PD; Robb, GR; Scott, JS; Sjögren, T; Swales, JG; Turnbull, AV; Wild, MJ | 1 |
| Chue, P; Mandel, FS; Therrien, F | 1 |
| Beniwal, M; Grewal, AS; Lather, V; Pandita, D; Sekhon, BS | 1 |
| Dossena, S; Nofziger, C; Patsch, W; Paulmichl, M; Soyal, SM | 1 |
| Andrisani, OM; Bi, P; Bidwell, CA; Castro, B; Durkes, A; Elzey, BD; Freeman, JL; Karki, A; Konieczny, SF; Kuang, S; Wang, C; Wirbisky, SE; Yue, F | 1 |
| Bai, YH; Cai, M; Chen, YC; Guo, L; McAlonan, GM; Tan, QR; Wang, HH; Wang, HN; Wang, Y; Wu, WJ; Zhang, RG; Zhang, YH; Zhang, ZJ | 1 |
| Chen, W; Li, S; Liu, HY; Long, L; Wang, LL | 1 |
| Dadić-Hero, E; Grahovac, T; Palijan, TZ; Petranović, D; Ružić, K; Sepić-Grahovac, D | 1 |
| Dadić-Hero, E; Grahovac, T; Ružić, K; Sabljić, V; Sepić-Grahovac, D | 1 |
| Chung, WY; Lee, J | 1 |
| Kaushik, S; Khan, A; Lindenmayer, JP; Parakadavil, M; Smith, RC; Tedeschi, F; Yusim, A | 1 |
| Adamidou, F; Anagnostis, P; Athyros, VG; Karagiannis, A; Katsiki, N; Kita, M; Mikhailidis, DP | 1 |
| Jones, NP; Olson, EJ; Pearce, GL; Sprecher, DL | 1 |
| Reusch, JE | 1 |
| Lebovitz, HE | 2 |
| Kotake, H | 1 |
| Kazdová, L; Kren, V; Krenová, D; Seda, O | 1 |
| Zimmet, P | 1 |
| Hoogwerf, BJ; Nambi, V; Sprecher, DL | 1 |
| Fedak, PW; Liu, PP; Verma, S; Wang, CH; Weisel, RD | 1 |
| Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL | 1 |
| Wyne, KL | 1 |
| Miller, JL | 1 |
| Chatterjee, VK; Gurnell, M; O'Rahilly, S; Savage, DB | 1 |
| Halimi, S | 1 |
| Ayyobi, AF; Brunzell, JD | 1 |
| Dagogo-Jack, S | 1 |
| Asaba, H; Auwerx, J; Doi, T; Hamakubo, T; Hamura, H; Iguchi, H; Ikeda, Y; Ioka, RX; Ito, S; Iwasaki, S; Kodama, T; Magoori, K; Naito, M; Sakai, J; Sumi, K; Tachibana, K; Tanaka, T; Uchiyama, Y; Watanabe, M; Watanabe, Y; Yamamoto, J; Yanagisawa, M | 1 |
| Sakai, J | 1 |
| Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ | 1 |
| Fredenrich, A; Gaudel, C; Grimaldi, PA; Holst, D; Jehl-Pietri, C; Lopez-Soriano, J; Luquet, S | 1 |
| Antoine, B; Beale, E; Benelli, C; Cadoudal, T; Chauvet, G; Collinet, M; Durant, S; Forest, C; Fouque, F; Leroyer, S; Quette, J; Reis, AF; Tordjman, J; Velho, G | 1 |
| Chen, Y; Frevert, EU; Fung, S; Jacobson, P; Jae, HS; Link, JT; Monzon, K; Richards, S; Sham, H; Sorensen, B; Wang, J; Winn, M | 1 |
| Tanaka, T | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Avila-Casado, C; Bautista-García, P; Franco, M; Johnson, RJ; Nakagawa, T; Sánchez-Lozada, LG; Soto, V; Tapia, E; Vega-Campos, IP; Zhao, L | 1 |
| Bao, W; Jucker, BM; Nerurkar, SS; Ohlstein, EH; Sarov-Blat, L; Steplewski, K; Willette, RN; Yue, TL | 1 |
| Csermely, P; Jermendy, G | 1 |
| Al-Majali, K; Betteridge, DJ; Kaplan, F | 1 |
| Hsueh, WA; Law, RE | 1 |
| Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS | 1 |
| Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS | 1 |
| Sewter, C; Vidal-Puig, A | 1 |
23 review(s) available for thiazoles and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome.
Topics: Animals; Humans; Metabolic Syndrome; PPAR delta; Thiazoles | 2016 |
Targeting SREBPs for treatment of the metabolic syndrome.
Topics: Animals; Humans; Metabolic Syndrome; Protein Kinase Inhibitors; Pyridines; Sterol Regulatory Element Binding Proteins; Thiazoles; Triterpenes | 2015 |
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Enzyme Inhibitors; Humans; Metabolic Syndrome; Obesity; Sulfonamides; Thiazoles | 2013 |
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Physical Fitness; Risk Factors; Thiazoles; Thrombosis; Vasodilation | 2002 |
Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metabolic Syndrome; Thiazoles | 2002 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Metabolic Syndrome; Thiazoles; Thiazolidinediones | 2002 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metabolic Syndrome; Metformin; Motor Activity; Obesity; Simvastatin; Thiazoles; Thiazolidinediones; Weight Loss | 2002 |
The need for reappraisal of type 2 diabetes mellitus management.
Topics: Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Primary Prevention; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
Insulin resistance syndrome. Description, pathogenesis, and management.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Mutation; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
The relationship of obesity to the metabolic syndrome.
Topics: Adiponectin; Adipose Tissue; Blood Proteins; Body Constitution; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Proteins; Thiazoles; Thiazolidinediones | 2003 |
[Therapeutic strategies for type 2 diabetes].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Metabolic Syndrome; Phenotype; Practice Guidelines as Topic; Thiazoles | 2003 |
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Metabolic Syndrome; Niacin; Thiazoles; Thiazolidinediones | 2003 |
Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management.
Topics: Blood Circulation; Diabetes Mellitus, Type 2; Environmental Exposure; Female; Genetic Predisposition to Disease; Humans; Hypoglycemic Agents; Incidence; Insulin; Life Style; Male; Metabolic Syndrome; Obesity; Prevalence; Risk Factors; Thiazoles; Thiazolidinediones; United States | 2003 |
[Activation of "fat burning sensor" peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome].
Topics: Animals; CCAAT-Enhancer-Binding Proteins; DNA-Binding Proteins; Fatty Acids; Glucose Tolerance Test; Humans; Insulin Resistance; Kruppel-Like Transcription Factors; Life Style; Metabolic Syndrome; Mice; Mice, Transgenic; Multigene Family; Muscle, Skeletal; Nuclear Proteins; Oxidation-Reduction; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Thiazoles; Transcription Factors; Transcription, Genetic | 2004 |
Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
Topics: Adipose Tissue; Animals; Fatty Acids; Insulin Resistance; Ligands; Macaca mulatta; Metabolic Syndrome; Muscle, Skeletal; Obesity; PPAR delta; Thiazoles | 2004 |
Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome.
Topics: Adipocytes; Adrenal Cortex Hormones; Animals; Esterification; Fatty Acids, Nonesterified; Gene Expression Regulation, Enzymologic; Glycerol; Glycerophosphates; Humans; Hypolipidemic Agents; Metabolic Syndrome; Mice; Phosphoenolpyruvate Carboxykinase (GTP); Thiazoles; Thiazolidinediones; Tretinoin; Triglycerides | 2005 |
[PPAR delta and metabolic syndrome].
Topics: Animals; Metabolic Syndrome; Mice; PPAR delta; Thiazoles | 2006 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
PPARS, insulin resistance and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
PPARgamma and atherosclerosis: effects on cell growth and movement.
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Syndrome; Muscle, Smooth, Vascular; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
PPARgamma and the thiazolidinediones: molecular basis for a treatment of 'Syndrome X'?
Topics: Animals; Humans; Insulin Resistance; Metabolic Syndrome; Microbodies; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2002 |
6 trial(s) available for thiazoles and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides | 2020 |
A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Triglycerides | 2013 |
The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Risk Factors; Schizophrenia; Thiazoles; Young Adult | 2014 |
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome; Weight Gain | 2017 |
Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Topics: Adult; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Blood Glucose; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Thiazoles; Time Factors; Treatment Outcome; Triglycerides | 2012 |
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
22 other study(ies) available for thiazoles and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Rationally designed PPARδ-specific agonists and their therapeutic potential for metabolic syndrome.
Topics: Humans; Metabolic Syndrome; PPAR delta; PPAR gamma; Thiazoles | 2017 |
Metabolic Syndrome and Amyloid Accumulation in the Aging Brain.
Topics: Aged; Aged, 80 and over; Aging; Amyloid; Aniline Compounds; Biomarkers; Blood Pressure; Brain; Female; Humans; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Phenanthrolines; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Thiazoles | 2018 |
Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate.
Topics: Acetanilides; Animals; Cyclic AMP; Female; Metabolic Syndrome; Muscle Relaxation; Muscle, Smooth; Myocytes, Smooth Muscle; Nitric Oxide; Nitric Oxide Synthase Type II; Rats; Receptors, Adrenergic, beta-3; Signal Transduction; Succinic Acid; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urothelium | 2018 |
Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis.
Topics: Acetanilides; Adipose Tissue, Brown; Adrenergic beta-3 Receptor Agonists; Animals; Caloric Restriction; Diet, High-Fat; Dioxoles; Drug Evaluation, Preclinical; Liver; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Thiazoles | 2019 |
Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.
Topics: Adult; Antipsychotic Agents; Female; Humans; Metabolic Syndrome; Piperazines; Polypharmacy; Schizophrenia, Paranoid; Thiazoles; Weight Gain | 2015 |
Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Blood Glucose; Body Weight; Brain; Crystallography, X-Ray; Cyclopropanes; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Hypoglycemic Agents; Insulin; Isoenzymes; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Molecular; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2014 |
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice.
Topics: Adipocytes; Animals; Biomarkers, Tumor; Cell Dedifferentiation; Cell Differentiation; Cell Lineage; Cell Proliferation; Cell Transformation, Neoplastic; Diabetes Mellitus, Experimental; Diamines; Dibenzazepines; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lipid Metabolism; Liposarcoma; Metabolic Syndrome; Mice, Inbred C57BL; PPAR gamma; Precancerous Conditions; PTEN Phosphohydrolase; Receptors, Notch; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Xenograft Model Antitumor Assays | 2016 |
Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.
Topics: Animals; Animals, Newborn; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Fatty Acids; Gene Expression; Insulin; Insulin Resistance; Leptin; Metabolic Syndrome; Mice; Mice, Obese; Oxidation-Reduction; PPAR delta; Sodium Glutamate; Thiazoles | 2008 |
Antipsychotic treatment--side-effect and/or metabolic syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Drug Substitution; Female; Humans; Metabolic Syndrome; Olanzapine; Piperazines; Psychotherapy; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Weight Gain | 2011 |
Weight gain--as possible predictor of metabolic syndrome.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dibenzothiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Metabolic Syndrome; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Thiazoles; Weight Gain | 2011 |
The role played by the peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) activator, GW501516, in control of fatty acid metabolism: a new potential therapeutic target for treating metabolic syndrome.
Topics: AMP-Activated Protein Kinases; Animals; Fatty Acids; Hypertriglyceridemia; Immunoblotting; Liver; Metabolic Syndrome; Mice; Nuclear Proteins; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphatidate Phosphatase; Phosphorylation; PPAR alpha; PPAR gamma; PPAR-beta; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Thiazoles; Trans-Activators; Transcription Factors; Triglycerides | 2011 |
Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Insulin; Lipids; Male; Metabolic Syndrome; Middle Aged; Piperazines; Polypharmacy; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Glucose; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Glitazones and heart failure: critical appraisal for the clinician.
Topics: Contraindications; Heart; Heart Failure; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Metabolic Syndrome; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Neurotransmitter Agents; Thiazoles; Vascular Resistance | 2003 |
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 2003 |
Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.
Topics: Animals; Dimethyl Sulfoxide; Enzymes; Fatty Acids, Nonesterified; Insulin Resistance; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; Oxidation-Reduction; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2003 |
Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Carbenoxolone; Enzyme Inhibitors; Humans; Metabolic Syndrome; Molecular Conformation; Piperazines; Sulfonamides; Thiazoles | 2006 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.
Topics: Animals; Blood Pressure; Body Weight; Energy Intake; Febuxostat; Fructose; Gout Suppressants; Kidney; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazoles; Xanthine Oxidase | 2008 |
In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Cytokines; Disease Models, Animal; Fatty Acids; Heart; Ketones; Male; Metabolic Syndrome; Myocardial Reperfusion Injury; PPAR delta; Proto-Oncogene Proteins c-akt; Rats; Rats, Zucker; RNA, Messenger; Thiazoles; Troponin I | 2008 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2002 |
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |